Veraxa Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation. The company was founded in 2021 and is based in…
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| Gruninger Marc director | Oct 28, 2026 | Purchase | 9,133 | $9.13K |
| Gruninger Marc director | Oct 27, 2026 | Purchase | 867 | $849.66 |
| Ziegler Christoph Samuel director | Oct 20, 2026 | Purchase | 30,000 | $32.7K |
Stock data for VRXA: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics